Company founded in Martinsried/Munich, Germany
First commercial partnership with Pharmacia-Upjohn
Move to the Innovation and Start-up Center for Biotechnology (IZB) Martinsried
IPO at the Frankfurt Stock Exchange
Start of an extensive partnership with Bayer AG
Presentation of the HuCAL antibody library
First HuCAL patent granted
Presentation of the HuCAL GOLD antibody library
Start of a strategic partnership with Schering AG
MorphoSys achieves a settlement of the CAT patent dispute
Dr. Simon E. Moroney receives the Bundesverdienstkreuz am Bande (Cross of the Order of Merit of the Federal Republic of Germany)
Start of a partnership with Pfizer
HuCAL antibodies to combat Alzheimer’s produce positive preclinical results
Start of a strategic partnership with Novartis
Presentation of the new research antibodies division, Antibodies by Design
Inclusion in the technology index TecDAX
MorphoSys achieves break even
The first HuCAL antibodies used in clinics
Acquisition of Biogenesis Group strengthens the research segment
First partnership with a Japanese pharmaceutical group
Acquisition of Serotec Group further strengthens the research segment
HuCAL antibodies to combat Alzheimer’s disease are used in clinics
MorphoSys announces development of new antibody platform technology
MorphoSys and Novartis forge one of the industry’s largest pharma-biotech R&D collaborations
First proprietary therapeutic antibody MOR103 enters clinical trials
MorphoSys unveils new antibody library, HuCAL PLATINUM
First HuCAL antibody enters phase 2 clinical trials
MorphoSys signs first infectious disease alliance with Daiichi-Sankyo
First proprietary therapeutic antibody in a patient setting
First in-licensing of a clinical antibody from Xencor
Aquisition of Sloning BioTechnology
MorphoSys presents new antibody technology arYla
MOR202 enters clinical development
MorphoSys presents new antibody technology Ylanthia
MorphoSys signs first industrial biotechnology alliance with Novozymes
MorphoSys announces positive clinical data for MOR103 in RA and MOR208 in CLL
With gantenerumab from Roche, the first partnered antibody program reaches late stage development
MorphoSys celebrates its 20th anniversary
MorphoSys signs first Ylanthia-based therapeutic partnership
MorphoSys completes sale of AbD Serotec to Bio-Rad
MorphoSys signs license agreement with GlaxoSmithKline for MOR103 program
MorphoSys signs strategic alliance with Celgene for MOR202 program
MorphoSys collaborator Novartis starts pivotal study with bimagrumab
MorphoSys and Merck Serono enter strategic immuno-oncology collaboration
MorphoSys and Emergent BioSolutions sign license agreement to co-develop and commercialize prostate cancer drug candidate MOR209/ES414
MorphoSys and Emergent BioSolutions announce the beginning of a joint clinical phase 1 trial of MOR209/ES414 in patients with metastatic, castration-resistant prostate cancer (mCRPC).
MorphoSys licensee Janssen submits an application seeking approval of guselkumab for the treatment of moderate to severe plaque psoriasis in the US (FDA) and Europe (EMA).
MorphoSys moves to new company headquarter in Semmelweisstraße in Planegg.